BioSpace Movers & Shakers, April 9 biospace.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from biospace.com Daily Mail and Mail on Sunday newspapers.
Published: Apr 09, 2021 By Alex Keown
Atara Biotherapeutics – Amie Krause was named Senior Vice President and Chief People Officer at Atara Biotherapeutics. In this role, Krause will be tasked with building a company culture that “rewards” values through actions and results. Prior to her tenure with Atara, Krause held several HR leadership positions at Amgen, including her role as Global HR Lead, Organizational Effectiveness during which she served as the human resources lead for Amgen’s global commercial operations covering the Americas, Europe, Asia, and the Middle East.
PsyBio Therapeutics – Michael Spigarelli was named chief medical officer of Ohio-based PsyBio. Before PsyBio Therapeutics, Spigarelli served as CMOr for Lumen Bioscience, a clinical-stage biopharmaceutical company developing biologic drugs for highly prevalent diseases. Prior to that, he served as Vice President of Medical Affairs for Immucor, Inc., a leading provider of transfusion and tran
PsyBio Strengthens its Leadership Team with Appointment of Dr Michael Spigarelli as Chief Medical Officer newswire.ca - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from newswire.ca Daily Mail and Mail on Sunday newspapers.
Posted on 440
According to Coherent Market Insights, the global therapeutic proteins and oral vaccines market is estimated to be valued at US$
201,042.7 million in 2020 and is expected to exhibit a CAGR of
6.7% over the forecast period (2020-2027).
Key Trends and Analysis:
The increasing prevalence of cancer diseases is expected to increase the demand for drugs, in turn fueling the
therapeutic protein and oral vaccine market growth in the near future. For instance, according to the World Health Organization report 2018, cancer causing infections such as Human Papilloma Virus (HPA) and hepatitis, are responsible for around 25% cancer cases in low and middle income countries such as Algeria, Angola, Botswana, Brazil, China, Gabon, Libya, Mauritius, Namibia, Seychelles, South Africa, and Tunisia.